Durham, North Carolina
Cancer biologic therapy trials in Durham, NC
36 cancer biologic therapy studies are recruiting participants at sites in Durham as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Durham at a glance
- 36 studies are recruiting at a site in Durham.
- By phase: Phase 1 (3), Phase 1/2 (1), Phase 2 (11), Phase 2/3 (3), Phase 3 (18).
- By sponsor: industry (15), government (11), university, hospital or other (10).
- By research area: Lymphoma (14), Lung Cancer (13), Breast Cancer (4), Melanoma (3), Pancreatic Cancer (1), Prostate Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Durham
Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT05564377 · updated
A Study of PHST001 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pheast Therapeutics
- Study site
- Duke Cancer Institute
- Registry record
- NCT06840886 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Duke University Medical Center
- Registry record
- NCT06876714 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Lung cancer studies recruiting in Durham
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Duke University Medical Center · Durham VA Medical Center
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT07388524 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Durham VA Medical Center
- Registry record
- NCT06096844 · updated
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Duke Cancer Institute
- Registry record
- NCT06646276 · updated
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- CatalYm GmbH
- Study site
- Duke University Medical Center
- Registry record
- NCT07246863 · updated
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- Phase 3
- All ages
- All sexes
- Sponsor
- Pierre Fabre Medicament
- Study site
- Duke Cancer Institute (Adults and Pediatrics)
- Registry record
- NCT03394365 · updated
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- CatalYm GmbH
- Study site
- Duke University Medical Center
- Registry record
- NCT07098988 · updated
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Durham VA Medical Center
- Registry record
- NCT06616584 · updated
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Duke University Medical Center
- Registry record
- NCT05624996 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Prostate cancer studies recruiting in Durham
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- Convergent Therapeutics
- Study site
- Duke University Medical Center
- Registry record
- NCT06549465 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Melanoma studies recruiting in Durham
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Duke University
- Study site
- Duke University Medical Center
- Registry record
- NCT05077137 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Durham, NC on ClinicalTrials.gov.
Lymphoma studies recruiting in Durham
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT06337318 · updated
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)
- Registry record
- NCT07634471 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT05675410 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Duke Cancer Institute
- Registry record
- NCT07188558 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Duke University Medical Center
- Registry record
- NCT05976763 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- Duke Blood Cancer Center
- Registry record
- NCT06500273 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT06124157 · updated
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Duke University Medical Center
- Registry record
- NCT05633615 · updated
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Duke University Medical Center
- Registry record
- NCT07220187 · updated
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Phase 3
- From 365 days, up to 25 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Duke University Medical Center
- Registry record
- NCT03959085 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Durham, NC on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Durham
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT06885034 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Ask about studies near Durham
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections